Enterprise Value

231.8B

Cash

9.708B

Avg Qtr Burn

N/A

Short % of Float

1.68%

Insider Ownership

0.25%

Institutional Own.

80.91%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TEPEZZA Details
Eye disease , Thyroid Eye Disease

Approved

Quarterly sales

TAVNEOS (Avacopan) (C5aR) Details
ANCA-Associated Vasculitis, Autoimmune disease

Approved

Quarterly sales

BLINCYTO® (blinatumomab) Details
B-cell acute lymphoblastic leukemia

Approved

Quarterly sales

KRYSTEXXA Details
Chronic refractory gout

Approved

Quarterly sales

BLINCYTO® (blinatumomab) Details
B-cell acute lymphoblastic leukemia

Approved

Quarterly sales

IMDELLTRA (Tarlatamab) (AMG 757) Details
Lung cancer, Cancer, Small cell lung cancer

Approved

Quarterly sales

Approved

Quarterly sales

BLA

Submission

LUMAKRAS/LUMYKRAS (sotorasib) Details
Non-small cell lung carcinoma

sNDA

Resubmission

Phase 3

Data readout

Olpasiran (AMG 890) Details
Atherosclerotic cardiovascular disease

Phase 3

Data readout

Phase 3

Data readout

UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details
Neuromuscular disease, Myasthenia gravis

Phase 3

Data readout

Nplate® Details
Chemo-induced thrombocytopenia

Phase 3

Data readout

TEZSPIRE Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Rocatinlimab Details
Atopic dermatitis

Phase 3

Data readout

TAVNEOS (Avacopan) (C5aR) Details
Skin disease/disorder, Hidradenitis suppurativa

Phase 3

Update

Phase 3

Initiation

Phase 3

Initiation

Fipaxalparant (AMG 670) (HZN-825) Details
Idiopathic pulmonary fibrosis

Phase 2b

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Dazodalibep (HZN-4920) Details
Kidney disease, Lupus nephritis, Autoimmune disease

Phase 2

Data readout

UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details
Kidney transplantation, Kidney disease

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details
Arthritis, Congenital adrenal hyperplasia, Genetic disorder, Autoimmune disease, Rheumatoid arthritis

Phase 2

Update

TAVNEOS (Avacopan) (C5aR) Details
Kidney disease, C3 Glomerulopathy

Phase 2

Update

Phase 2

Update

Tezspire Details
Chronic obstructive pulmonary disease

Phase 2a

Update

HZN-457 Details
Chronic refractory gout

Phase 1

Data readout

Phase 1

Update